Onconetix shareholders approve reverse stock split ratio range 1:10 to 1:150

Onconetix, Inc.

Reverse stock split proposal approved: 11,956,279 For, 4,222,940 Against, 153,929 Abstentions.
Board authorized to select exact ratio (1-for-10 to 1-for-150) anytime within one year of May 30, 2025.
Adjournment proposal also approved: 13,570,278 For, 2,367,590 Against, 395,280 Abstentions.
44,358,422 shares of common stock were outstanding as of the April 14, 2025 record date.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.